← Leaderboards
F Javier Piedrafita
Sidney Kimmel Cancer Center
$5,330,033
Attributed
$7,047,750
Total exposure
6
Grants
4
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $820.5K · FY2005–18$1M$750K$500K$250K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
Funding mix
By agency
NIH$7,047,750 · 6
By mechanism
R01$6,165,636 · 4
R21$882,114 · 2
Top collaborators
- Adel Nefzi7 shared
Most similar at Sidney Kimmel Cancer Center
Same institution · by research overlap
- Magnus Pfahl$863,656
Others in their field
Top investigators on “Retinoids”
- Krzysztof Palczewski · University Of California-Irvine$33,394,447
- John E Connett · University Of Minnesota Twin Cities$20,977,187
- Lorraine J Gudas · Sloan-Kettering Institute For Cancer Res$18,380,817
- Joseph L Napoli · University Of California Berkeley$14,913,548
- William S Blaner · Columbia University Health Sciences$13,070,813
- Garrett M Brodeur · Children'S Hospital Of Philadelphia$12,100,423
Research focus
RetinoidsInterestBaseCellsInhibitor/AntagonistAnticancer ActivityLeadPreventIn VitroIn VivoReportingAgonistAnimal ModelApoptosisClinicStructureFamilyMediatingAnalogIncidenceSeriesFutureReceptorHormones
Grant awards (21)
Novel RORgamma antagonists for inflammation and autoimmune disease$489,026
R01 · FY2018 · AI
Novel RORgamma antagonists for inflammation and autoimmune disease$584,371
R01 · FY2017 · AI
Novel RORgamma antagonists for inflammation and autoimmune disease$590,333
R01 · FY2016 · AI · contact PI
LMTK3 inhibitors for the treatment of breast cancer$199,275
R21 · FY2016 · CA · contact PI
Novel RORgamma antagonists for inflammation and autoimmune disease$580,731
R01 · FY2015 · AI · contact PI
LMTK3 inhibitors for the treatment of breast cancer$239,730
R21 · FY2015 · CA · contact PI
Novel RORgamma antagonists for inflammation and autoimmune disease$751,968
R01 · FY2014 · AI · contact PI
Novel adamantyl arotinoids for the prevention and treatment of prostate cancer$241,755
R01 · FY2012 · CA · contact PI
Novel adamantyl arotinoids for the prevention and treatment of prostate cancer$241,755
R01 · FY2011 · CA · contact PI
Novel adamantyl arotinoids for the prevention and treatment of prostate cancer$249,232
R01 · FY2010 · CA · contact PI
Novel adamantyl arotinoids for the prevention and treatment of prostate cancer$239,857
R01 · FY2009 · CA · contact PI
Novel adamantyl arotinoids for the prevention and treatment of prostate cancer$157,501
R01 · FY2008 · CA · contact PI
Novel adamantyl arotinoids for the prevention and treatment of prostate cancer$112,500
R01 · FY2008 · CA · contact PI
Rational Discovery of ROR Gamma Modulators$231,828
R21 · FY2007 · GM · contact PI
Rational Discovery of ROR Gamma Modulators$211,281
R21 · FY2006 · GM · contact PI
Analysis of Retinoid Mediated Anti Cancer Activities$329,344
R01 · FY2005 · CA
Analysis of Retinoid Mediated Anti Cancer Activities$329,344
R01 · FY2004 · CA
Analysis of Retinoid Mediated Anti Cancer Activities$370,512
R01 · FY2003 · CA
RETINOID INDUCED APOPTOSIS IN LEUKEMIA CELLS$316,186
R01 · FY2002 · CA
RETINOID INDUCED APOPTOSIS IN LEUKEMIA CELLS$294,904
R01 · FY2001 · CA
RETINOID INDUCED APOPTOSIS IN LEUKEMIA CELLS$286,317
R01 · FY2000 · CA